|
|
|
题名
|
作者
|
年代
|
出处
|
被引量
|
| 1 | Missed diagnosis of early gastric cancer or high-grade intraepithelial neoplasia显示文摘AIM: To investigate the causes of missed diagnosis of early gastric cancer (EGC) or high-grade intraepithelial neoplasia (HGIN) in Chongqing, China. METHODS: The present study summarizes 103 cases of EGC/HGIN detected by esophagogastroduodenos-copy (EGD) and pathological analysis from January 2010 to December 2011. Dimethyl silicone oil was administrated orally 15 min before the EGD procedures. The stomach was cleaned by repeated washing with saline when the gastroscope entered the stomach cavity. Suspected EGC lesions were subject to conventional biopsy sampling and pathological examinations. The correlation between lesion locations, endoscopic morphology of cancerous sites, training level of the examiners, pathological biopsies, and missed diagnosis was analyzed. RESULTS: Twenty-three cases were missed among the 103 cases (22.23%) of EGC/HGIN. The rate of missed EGC in the gastroesophageal junction (8/19, 42.1%) was significantly higher than at other sites (15/84, 17.86%) (χ2 = 5.253, P = 0.022). In contrast, the rate of missed EGC in the lower stomach body (2/14, 14.29%) was lower than at other sites (21/89,23.6%), but there were no significant differences (χ2 = 0.289, P = 0.591). The rate of missed EGC in the gastric antrum (5/33, 15.15%) was lower than at other sites (18/70, 25.71%), but there were no significant differences (χ2 = 1.443, P = 0.230). Endoscopists from less prestigious hospitals were more prone to not diagnosing EGC than those from more prestigious hospitals (χ2 = 4.261, P = 0.039). When the number of biopsies was < 4, the rate of missed diagnosis was higher (20/23, 89.96%) than for when there were > 4 biopsies (3/23, 13.04%) (P < 0.001). In addition, there was no significant difference in the rate of missed diagnosis in patients with 1-3 biopsy specimens (χ2 = 0.141, P = 0.932). CONCLUSION: Endoscopists should have a clear understanding of the anatomical characteristics of the esophagus/stomach, and endoscopic identification of early lesions increases with the number of biopsies. | Wei Ren Jin Yu Zhi-Mei Zhang Yuan-Kun Song Yi-Hui Li Lei Wang | 2013 | World Journal of Gastroenterology2013，19，13： | 58 |
| 2 | Diagnostic and therapeutic biomarkers in pancreaticobiliary malignancy显示文摘Pancreatic ductal adenocarcinoma(PDAC) and cholangiocarcinoma(CCA) are two malignancies that carry significant morbidity and mortality. The poor prognoses of these cancers are strongly related to lack of effective screening modalities as well as few therapeutic options. In this review, we highlight novel biomarkers that have the potential to be used as diagnostic, prognostic and predictive markers. The focus of this review is biomarkers that can be evaluated on endoscopically-obtained biopsies or brush specimens in the pre-operative setting. We also provide an overview of novel serum based markers in the early diagnosis of both PDAC and CCA. In pancreatic cancer, the emphasis is placed on prognostic and theranostic markers, whereas in CCA the utility of molecular markers in diagnosis and prognosis are highlighted. | Domenico Viterbo Valerie Gausman Tamas Gonda | 2016 | World Journal of Gastrointestinal Endoscopy2016，8，3： | 6 |
| 3 | Histological and clinical evaluation of marginal donor kidneys before transplantation: Which is best?显示文摘Organ shortage represents one of the major limitations to the development of kidney transplantation.To increase the donor pool and to answer the ever increasing kidney request,physicians are recurring to marginal kidneys as kidneys from older donors,from hypertensive or diabetic donors and from nonheart beating donors.These kidneys are known to have frequently a worse outcome in the recipients.To date major problem is to evaluate such kidneys in order to use or to discard them before transplantation.The use of such kidneys create other relevant question as whether to use them as single or dual transplant and to allocate them fairly according transplant programs.The pre-transplant histological evaluation,the clinical evaluation of the donor or both the criteria joined has been used and according the time each criterion prevailed over the others.Aim of this review has been to examine the advantages and the drawbacks of any criterion and how they have changed with time.To date any criterion has several limitations and several authors have argued for the development of new guidelines in the field of the kidney evaluation for transplantation.Several authors argue that the use of omic technologies should improve the organ evaluation and studies are ongoing to evaluate these technologies either in the donor urine or in the biopsies taken before transplantation. | Maurizio Salvadori Aris Tsalouchos | 2019 | World Journal of Transplantation2019，9，4： | 0 |
| 4 | Is the determination of ctDNA a scientific “spy” that foresees cancer?显示文摘Since 1948, circulating tumour DNA(ctDNA) was first identified in human blood. ctDNA is in fact DNA shed by tumour cells from all metastatic tumour locations throughout the whole body, and is thrown into the bloodstream and can then be isolated by a standard blood draw. Using this technique scientists can obtain a wide view of tumour heterogeneity, identify different mechanisms of drug resistance, what is its predominance and the clinical rational of precision cancer medicine become a part of our daily practice. Secondly, early detection of cancer may also contribute to global decrease in cancer mortality. | Joana Espiga de Macedo Manuela Machado | 2017 | World Journal of Respirology2017，7，2： | 0 |
| 5 | Histopathology of hepatocellular carcinoma-when and what显示文摘When do you need to take biopsies of the liver,and what information will you get is the topic of this review on hepatocellular carcinoma(HCC).If,clinically,the differential diagnosis of HCC after imaging is suggested,a biopsy has become obligatory as a diagnostic confirmation of HCC in the non-cirrhotic liver prior to definitive therapeutic interventions,as well as in a palliative therapy concept.In the case of hepatic lesions with an uncharacteristic contrast uptake,a biopsy should be performed immediately to confirm the diagnosis of HCC.After diagnosing HCC,a treatment strategy is evaluated.Further,the biopsy,or in case of surgical treatment,the resected tissue,shows us the different subtypes of HCC,with the steatohepatitic subtype being the most common and the lymphocyte-rich subtype being the least common.Further,the histological grade of HCC is determined according to the grading system of the WHO or the Edmonson and Steiner System.Through biopsies,HCC can be differentiated from intrahepatic cholangiocarcinoma or combined hepatocellular-cholangiocarcinoma or metastases of other malignant tumors,especially metastases of the gastrointestinal tract.In summary,biopsies are fundamental in the diagnosis of HCC. | Doreen Maria Gisder Andrea Tannapfel Iris Tischoff | 2022 | Hepatoma Research2022，8，1： | 0 |
您所在的机构暂未开通此部分的功能，请联系管理员